Global experts from the Progressive MS Alliance are meeting in London in April and May to review the applications they have received for funding.
07 Apr 2014
MSIF has announced a series of changes to its communications and information, after the agreement by MSIF’s board of trustees of the organisation’s new communication and information strategy
17 Jul 2014
This issue of MS in focus is dedicated to elimination dysfunction; that is, bladder and bowel problems. Often these two topics are discussed together because the same MS lesions in the spinal cord can impair the transmission of messages that control both these functions.
14 Jul 2014
Read personal stories of MS from around the world
Christelle from South Africa says: "MS has had a massive impact on my life. I used to love dancing, but can do that no longer! I was quite ambitious and competitive, but now, at age 41, I have to focus on the here and now. Online shopping is the best!"
MS in focus 23 ready to download
International experts writing in this edition include Sally Shaw from Australia on who to trust online, the UK’s George Pepper writing on social media, and Lauren E Hansen from the USA on empowerment.
New "MS in focus" on cognition published
Find out why cognition problems occur in MS, how to identify cognitive problems, treatment and management of the symptom, and day-to-day living with cognitive difficulties.
Perivascular spaces in MS patients at 7 Tesla MRI: a marker of neurodegeneration?
MS patients displayed more Virchow-Robin spaces (VRS) compared to healthy controls, especially in superior areas of the brain. VRS in MS patients were associated with supratentorial brain atrophy, but not with lesion load.
Bringing CLARITY to gray matter atrophy
The use of both MRI and CLARITY represents a novel approach to better discern neuropathological processes in intact tissues in 3D in a variety of neurodegenerative diseases, like multiple sclerosis.
JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene
JCV GCN should be considered in patients on natalizumab presenting with progressive cerebellar symptoms and cerebellar atrophy, and is associated with mutations in the JCV VP1 gene.
Allliance announces first round of grants
The 22 projects were chosen from 195 research proposals submitted by researchers in 22 countries.
Seventh edition of the Arabic MS newsletter now out
12 organisations in 11 Arabic countries have contributed to the latest edition of Tawasol. Reports cover World MS Day and participation in MSIF meetings. There is also a contribution from Saudi Arabia for the first time. English summary available.
Definitions of MS reviewed
The International Advisory Committee on Clinical Trials in MS has reviewed the current definitions of MS and has recommended reclassing progressive-relapsing as an active form of primary progressive MS.
Find your nearest MS organisation
Multiple Sclerosis International Federation
Address: 3rd Floor Skyline House 200 Union Street London SE1 0LX
MSIF is a charity and company limited by guarantee, registered in England and Wales.
Company No: 05088553. Registered Charity No: 1105321
© Multiple Sclerosis International Federation
<%=DateTime.Now.ToString("dddd, dd MMMM yyyy HH:mm")%>